You have free access to this content

Cancer

Cover image for Vol. 117 Issue 10

15 May 2011

Volume 117, Issue 10

Pages 2017–2238

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. You have free access to this content
    2. You have free access to this content
      Three national cancer clinical research groups to merge (page 2018)

      Carrie Printz

      Version of Record online: 26 APR 2011 | DOI: 10.1002/cncr.26177

    3. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. You have free access to this content
      Metabolic risk factors in prostate cancer (pages 2020–2023)

      David I. Chu and Stephen J. Freedland

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25749

      The biology of prostate cancer is influenced by the metabolic profile of each individual. The authors examined available evidence on interlinking prostate cancer with obesity, diabetes, and other metabolic syndrome components. See related article pp.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis (pages 2024–2034)

      Min Fang, Jessica Toher, Martin Morgan, Jerry Davison, Susan Tannenbaum and Kevin Claffey

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25770

      • original image
      • original image
      • original image
      • original image

      The authors used single-nucleotide polymorphism (SNP) arrays to compare overall copy number aberrations as well as loss of heterozygosity of the entire human genome in estrogen receptor (ER)-positive and ER-negative breast carcinomas. SNP arrays were capable of detecting both genetic imbalance and acquired uniparental disomy to discriminate ER-negative breast cancer from ER-positive breast cancer.

    2. You have free access to this content
      Clinicopathologic factors of the recurrent tumor predict outcome in patients with ipsilateral breast tumor recurrence (pages 2035–2043)

      Valerie Panet-Raymond, Pauline T. Truong, Cheryl Alexander, Mary Lesperance, Rachel E. McDonald and Peter H. Watson

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25767

      • original image
      • original image

      The role of clinicopathologic characteristics of the recurrent tumor in determining survival in a cohort with ipsilateral breast tumor recurrence (IBTR) was investigated. Time to recurrence ≤48 months, lymphovascular invasion positive status, estrogen receptor negative status, high-grade histology, and close/positive margins independently determined prognosis, with 2 or more of these features at recurrence significantly associated with poor overall survival after IBTR.

    3. Gastrointestinal Disease
      You have free access to this content
      Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma (pages 2044–2049)

      Avo Artinyan, Daniel A. Anaya, Shaun McKenzie, Joshua D. I. Ellenhorn and Joseph Kim

      Version of Record online: 18 NOV 2010 | DOI: 10.1002/cncr.25763

      • original image
      • original image

      Surgical resection can improve survival for patients with pancreatic adenocarcinoma, but the optimal timing to administer adjunct therapies has yet to be determined. This population-based study shows that neoadjuvant therapy is associated with a survival advantage over adjuvant chemotherapy.

    4. You have free access to this content
      A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy (pages 2050–2057)

      Hei-Cheul Jeung, Sun Young Rha, Chong Kun Im, Sang Joon Shin, Joong Bae Ahn, Woo Ick Yang, Jae Kyung Roh, Sung Hoon Noh and Hyun Cheol Chung

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25729

      • original image

      In this phase 2 study of advanced gastric cancer, docetaxel and S-1 were favored over docetaxel and cisplatin for further phase 3 study. SPARC expression may help to individualize therapy in the future.

    5. Genitourinary Disease
      You have free access to this content
      Overtreatment of men with low-risk prostate cancer and significant comorbidity (pages 2058–2066)

      Timothy J. Daskivich, Karim Chamie, Lorna Kwan, Jessica Labo, Roland Palvolgyi, Atreya Dash, Sheldon Greenfield and Mark S. Litwin

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25751

      • original image
      • original image
      • original image

      In a cohort of men with newly diagnosed prostate cancer, 54% of those who had Charlson scores ≥3 were treated aggressively for low-risk prostate cancer despite a 70% probability of other-cause mortality at 10 years after treatment. Unlike men with advanced age at diagnosis, men with significant comorbidities had substantial rates of overtreatment for low-risk disease.

    6. You have free access to this content
      Etiologic role of human papillomavirus infection in bladder carcinoma (pages 2067–2076)

      Kazuyoshi Shigehara, Toshiyuki Sasagawa, Shohei Kawaguchi, Takao Nakashima, Masayoshi Shimamura, Yuji Maeda, Hiroyuki Konaka, Atsushi Mizokami, Eitetsu Koh and Mikio Namiki

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25777

      • original image
      • original image
      • original image
      • original image

      The authors identified human papillomavirus (HPV) DNA in some frozen clinical bladder carcinoma samples and investigated the expression of surrogate markers for high-risk HPV-E7 oncoprotein, cyclin-dependent kinase inhibitor 2A (p16-INK4a), and minichromosome maintenance protein-7 (mcm-7). The current results indicated that HPV may be a causative agent of some low-grade bladder carcinomas that develop in younger patients.

    7. You have free access to this content
      Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer (pages 2077–2085)

      Matthew R. Smith, Richard Cook, Ker-Ai Lee and Joel B. Nelson

      Version of Record online: 16 NOV 2010 | DOI: 10.1002/cncr.25762

      • original image
      • original image

      By using data from the placebo group of a previously reported international randomized study of men with progressive castration-resistant prostate cancer and no detectable metastases, the authors observed that baseline prostate-specific antigen was significantly associated with time to first bone metastasis, bone metastasis-free survival, and overall survival. Other disease and host characteristics, including body mass index and bone turnover markers, were not consistently associated with clinical outcomes.

    8. You have free access to this content
      Prostate cancer risk in the Swedish AMORIS study : The interplay among triglycerides, total cholesterol, and glucose (pages 2086–2095)

      Mieke Van Hemelrijck, Hans Garmo, Lars Holmberg, Göran Walldius, Ingmar Jungner, Niklas Hammar and Mats Lambe

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25758

      • original image
      • original image

      The authors'; findings support the hypothesis that factors of the glucose and lipid metabolism influence pCa risk and indicate another reason to fight the increasing prevalence of obesity and dyslipidemia. Competing risk analyses showed that it is important to take into account the long natural history and age distribution of pCa when interpreting results.

    9. Gynecologic Oncology
      You have free access to this content
      KIT gene mutation and amplification in dysgerminoma of the ovary (pages 2096–2103)

      Liang Cheng, Lawrence M. Roth, Shaobo Zhang, Mingsheng Wang, Michael J. Morton, Wenxin Zheng, Fadi W. Abdul Karim, Rodolfo Montironi and Antonio Lopez-Beltran

      Version of Record online: 30 NOV 2010 | DOI: 10.1002/cncr.25794

      • original image
      • original image

      The purpose of this study was to characterize KIT abnormalities by way of mutation, fluorescence in situ hybridization, and immunohistochemical analysis and correlate the findings with various clinicopathological parameters and other known genetic abnormalities frequently found in the tumors of germ origin. The findings suggested that KIT mutations occur in approximately one-third of dysgerminomas and are associated with advanced tumor stage. Patients whose dysgerminomas have KIT alterations may be potentially helped by targeted therapy.

    10. You have free access to this content
      Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer (pages 2104–2111)

      Chel Hun Choi, Yoo-Young Lee, Tae-Jong Song, Hwang-Shin Park, Min Kyu Kim, Tae-Joong Kim, Jeong-Won Lee, Je-Ho Lee, Duk-Soo Bae and Byoung-Gie Kim

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25710

      • original image
      • original image
      • original image

      The newly developed topoisomerase I inhibitor belotecan (CKD-602) combined with carboplatin is a well-tolerated regimen with activity in recurrent EOC.

    11. Head and Neck Disease
      You have free access to this content
      Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma (pages 2112–2119)

      Heather D. Brooks, Bonnie S. Glisson, B. Nebiyou Bekele, Lawrence E. Ginsberg, Adel El-Naggar, Kirk S. Culotta, Naoko Takebe, John Wright, Hai T. Tran and Vassiliki A. Papadimitrakopoulou

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25769

      • original image
      • original image
      • original image

      This is a report of what to the authors'; knowledge is the first phase 2 study of dasatinib in head and neck cancer accompanied by extensive serum cytokine and angiogenic factor profiling. The activity of dasatinib in patients with metastatic/recurrent head and neck cancer is modest and administration via percutaneous feeding tube feasible, and prognostic biologic parameters for patient outcome have been identified.

      Corrected by:

      Erratum: Erratum: Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma

      Vol. 118, Issue 9, 2560, Version of Record online: 1 SEP 2011

    12. You have free access to this content
      Radiation-induced osteosarcomas of the calvarium and skull base (pages 2120–2126)

      Akash J. Patel, Vikas Y. Rao, Benjamin D. Fox, Dima Suki, David M. Wildrick, Raymond Sawaya and Franco DeMonte

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25734

      • original image
      • original image
      • original image
      • original image

      Radiation-induced osteosarcoma of the cranium is an uncommon but dire complication of radiotherapy. These tumors are locally aggressive, and despite aggressive surgical and medical management, they have a high rate of local recurrence and mortality.

    13. Hematologic Malignancies
      You have free access to this content
      Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response (pages 2127–2135)

      Asher Chanan-Khan, Kena C. Miller, David Lawrence, Swaminathan Padmanabhan, Austin Miller, Francisco Hernandez-Illatazurri, Myron S. Czuczman, Paul K. Wallace, Jerome B. Zeldis and Kelvin Lee

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25748

      • original image
      • original image
      • original image

      In patients with chronic lymphocytic leukemia, lenalidomide induces an immune-mediated response called tumor flare reaction that mimics disease progression, the intensity of which may be correlated with clinical response. Diagnosis and understanding of this phenomenon can direct therapeutic decisions and affect treatment outcome.

    14. You have free access to this content
      Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone (pages 2136–2144)

      Ulrike Klein, Anna Jauch, Thomas Hielscher, Jens Hillengass, Marc S. Raab, Anja Seckinger, Dirk Hose, Anthony D. Ho, Hartmut Goldschmidt and Kai Neben

      Version of Record online: 4 DEC 2010 | DOI: 10.1002/cncr.25775

      • original image
      • original image

      The prognostic significance of translocation t(4;14) may be ameliorated or eliminated in patients treated with lenalidomide and dexamethasone, whereas the presence of deletion del(17p13) or +1q21 is associated with a dismal overall survival. The presence of t(11;14) and del(13q14) as exclusive chromosomal aberrations appears to have no impact on outcome.

    15. You have free access to this content
      Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (pages 2145–2155)

      Fabio P. S. Santos, Dan Jones, Wei Qiao, Jorge E. Cortes, Farhad Ravandi, Elihu E. Estey, Dushyant Verma, Hagop Kantarjian and Gautam Borthakur

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25670

      • original image
      • original image

      Unlike patients who had normal karyotype acute myeloid leukemia (NK-AML), the presence of FMS-like tyrosine kinase 3 (FLT3) mutations had no impact on the outcome of patients in good-risk or poor-risk cytogenetic subgroups. In patients who had NK-AML, higher FLT3-internal tandem duplication mutant allele burden was associated with poorer outcomes, whereas patients who had a low allele burden had outcomes comparable to those achieved by patients who had wild-type FLT3.

    16. You have free access to this content
      Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse (pages 2156–2162)

      Mario Tiribelli, Antonella Geromin, Angela Michelutti, Margherita Cavallin, Annalisa Pianta, Dora Fabbro, Domenico Russo, Giuseppe Damante, Renato Fanin and Daniela Damiani

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25753

      • original image

      A significant correlation was found between ABCG2 protein overexpression and FLT3-ITD in a group of 166 AML patients. Neither ABCG2 overexpression nor FLT3-ITD had any impact on achievement of complete response after induction with a fludarabine-based induction therapy, but relapse-free survival was shorter in cases with concomitant overexpression of ABCG2 and FLT3-ITD, with disease-free survival of only 36% and 28% at 1 and 3 years, respectively.

    17. You have free access to this content
      Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia (pages 2163–2169)

      Lukas Weiss, Thomas Melchardt, Alexander Egle, Christoph Grabmer, Richard Greil and Inge Tinhofer

      Version of Record online: 18 NOV 2010 | DOI: 10.1002/cncr.25752

      • original image
      • original image
      • original image
      • original image

      Flow-cytometric analysis of regulatory T cells in peripheral blood from 102 patients with early to intermediate stage chronic lymphocytic leukemia revealed that increased regulatory T-cell levels are associated significantly with a shorter time to initial treatment. Relative numbers of regulatory T cells had significant prognostic power for predicting the time to initial treatment in multivariate Cox regression analysis compared with established risk parameters.

    18. Hepatobiliary Disease
      You have free access to this content
      AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma : By the AFC-IHCC-2009 study group (pages 2170–2177)

      Olivier Farges, David Fuks, Yves-Patrice Le Treut, Daniel Azoulay, Alexis Laurent, Philippe Bachellier, Gennaro Nuzzo, Jacques Belghiti, François René Pruvot and Jean Marc Regimbeau

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25712

      • original image
      • original image
      • original image
      • original image

      This year the AJCC has implemented a new staging system for intrahepatic cholangiocarcinoma that has not been validated yet. The present study shows that it is more discriminative than the 2 Western and the 2 Eastern classifications previously used.

    19. Lung Disease
      You have free access to this content
      A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer (pages 2178–2185)

      Ji-Youn Han, Kun Young Lim, Sun Young Yu, Tak Yun, Heung Tae Kim and Jin Soo Lee

      Version of Record online: 30 NOV 2010 | DOI: 10.1002/cncr.25790

      • original image
      • original image

      The addition of simvastatin to irinotecan and cisplatin improved efficacy in ever-smokers with extensive-disease small cell lung cancer. The survival benefit from this combination was apparent in heavy smokers.

    20. You have free access to this content
      Lysyl oxidase: A lung adenocarcinoma biomarker of invasion and survival (pages 2186–2191)

      May-Lin Wilgus, Alain C. Borczuk, Mark Stoopler, Mark Ginsburg, Lyall Gorenstein, Joshua R. Sonett and Charles A. Powell

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25768

      • original image
      • original image
      • original image

      Lysyl oxidase (LOX) is required for extracellular matrix formation and contributes to the tumor stroma microenvironment. The results of the current study demonstrated that expression of LOX is an independent predictor of survival in patients with early stage lung adenocarcinoma.

    21. Melanoma
      You have free access to this content
      Overall survival and PD-L1 expression in metastasized malignant melanoma (pages 2192–2201)

      Jules Gadiot, Anna I. Hooijkaas, Andrew D. M. Kaiser, Harm van Tinteren, Hester van Boven and Christian Blank

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25747

      • original image
      • original image
      • original image
      • original image
      • original image

      In a cohort of European patients with melanoma, increased frequency of programmed cell death ligand–1 (PD-L1)+ tumor cells was found during disease progression, but PD-L1 expression was not found to be associated with patients' overall survival.

    22. You have free access to this content
      A phase 2 trial of dasatinib in advanced melanoma (pages 2202–2208)

      Harriet M. Kluger, Arkadiuz Z. Dudek, Carrie McCann, Jean Ritacco, Nadine Southard, Lucia B. Jilaveanu, Annette Molinaro and Mario Sznol

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25766

      • original image

      The purpose of this phase 2 trial was to assess the activity of dasatinib in melanoma. Dasatinib has limited activity in unselected melanoma patients, and predictive biomarkers are necessary to identify patients more likely to respond to therapy.

    23. Discipline

      Epidemiology
      You have free access to this content
      Update on mammography trends : Comparisons of rates in 2000, 2005, and 2008 (pages 2209–2218)

      Nancy Breen, Jane F. Gentleman and Jeannine S. Schiller

      Version of Record online: 30 NOV 2010 | DOI: 10.1002/cncr.25679

      • original image

      Overall, with exceptions for some subgroups, mammography rates did not continue to decline between 2005 and 2008. However, again in 2008, the percentage of women aged ≥40 years who had a mammogram within the last 2 years was below the Healthy People 2010 objective of 70% that was met in 2000.

    24. Pediatric Oncology
      You have free access to this content
      Association of cyclophosphamide use with dental developmental defects and salivary gland dysfunction in recipients of childhood antineoplastic therapy (pages 2219–2227)

      Susan Gyea-Su Hsieh, Sally Hibbert, Peter Shaw, Verity Ahern and Manish Arora

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25704

      • original image
      • original image
      • original image

      In a cohort of 106 recipients of childhood antineoplastic therapy, cumulative cyclophosphamide doses of 7500 mg/m2 or more were significantly associated with an increased severity of dental developmental defects, measured using a validated index. Recipients of cyclophosphamide also had significantly increased odds of exhibiting very low saliva flow (<0.7 mL/min).

    25. You have free access to this content
      Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in Southeast Brazil (pages 2228–2235)

      Ana Luiza Seidinger, Maria José Mastellaro, Fernanda Paschoal Fortes, Juliana Godoy Assumpção, Izilda Aparecida Cardinalli, Mônica Aparecida Ganazza, Raul Correa Ribeiro, Silvia Regina Brandalise, Simone dos Santos Aguiar and José Andrés Yunes

      Version of Record online: 29 DEC 2010 | DOI: 10.1002/cncr.25826

      • original image
      • original image

      The inherited, low-penetrant arginine-to-histidine substitution at codon 337 (R337H) of the tumor protein 53 gene (TP53) has been associated not only with adrenal cortical tumors but also with pediatric choroid plexus carcinoma and osteosarcoma. In this study, a history of familial cancer provided no evidence to suspect that a germline TP53 mutation was present among patients with this mutation, prompting the authors to suggest the use of more inclusive clinical criteria for the identification of potential carriers of low-penetrance TP53 mutations.

  4. Correspondence

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. You have free access to this content
    2. You have free access to this content
      Reply to induction therapy and outcome in acute myeloid leukemia (page 2237)

      Jacob M. Rowe, Haesook T. Kim and Martin S. Tallman

      Version of Record online: 18 NOV 2010 | DOI: 10.1002/cncr.25702

  5. Erratum

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. You have free access to this content
      Erratum: Immunohistochemical Surrogate Markers of Breast Cancer Molecular Classes Predicts Response to Neoadjuvant Chemotherapy (page 2238)

      Rohit Bhargava, Sushil Beriwal, David J. Dabbs, Umut Ozbek, Atilla Soran, Ronald R. Johnson, Adam M. Brufsky, Barry C. Lembersky and Gretchen M. Ahrendt

      Version of Record online: 10 NOV 2010 | DOI: 10.1002/cncr.25798

      This article corrects:

SEARCH

SEARCH BY CITATION